Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia.
Wondwosen MebratuShambel WedajoSemira MohammedAbel EndawkieYeshiwork DamtewPublished in: Scientific reports (2022)
Tuberculosis (TB) is major public health concern and Isoniazid Preventive Therapy (IPT) helps to prevent TB development among patients living with human immune deficiency virus (PLWHIV). However, the evidence is limited especially in the study area. Therefore, this study aimed to determine the prevalence and factors associated with TB among IPT users and non-IPT users of PLWHIV in Dessie, Ethiopia. A comparative cross-sectional study was employed for1 month in Dessie. A total of 326 respondents were selected using systematic random sampling. Bivariable and multivariable logistic regression analyses were computed to identify factors associated with Tuberculosis. In multivariable analysis, AOR with 95% CI was used to declare statistically significant variables with TB. The prevalence of TB among non-IPT users was 48.5%, (95% CI 40.8-56.2%), and among IPT users was 8%, (95% CI 5-13%). Cotrimoxazole prophylaxis therapy (CPT) (AOR = 5.835, 95% CI 2.565-13.274), IPT (AOR = 10.359, 95% CI 4.054-26.472), ART adherence (AOR = 30.542, 95% CI 12.871-72.475), and believing that IPT use prevents TB (AOR = 0.093, 95% CI 0.018-0.484) were statistically significant factors. The prevalence of TB was higher among non-IPT users than among IPT users. Therefore, efforts should be strengthened to implement widespread use of IPT among adult PLWHIV.
Keyphrases
- mycobacterium tuberculosis
- pulmonary tuberculosis
- public health
- risk factors
- end stage renal disease
- hiv infected
- antiretroviral therapy
- magnetic resonance imaging
- chronic kidney disease
- endothelial cells
- stem cells
- ejection fraction
- hepatitis c virus
- hiv positive
- type diabetes
- human immunodeficiency virus
- young adults
- quality improvement
- bone marrow
- peritoneal dialysis
- insulin resistance
- induced pluripotent stem cells
- contrast enhanced
- adverse drug